Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1613 1617 1645 1767
This examiner grants 55% of resolved cases
Alma Pipic is an examiner in Tech Center 1700 and Art Unit 1613. The examiner has 722 resolved cases and an allowance rate of 54.6 percent. This indicates a moderate level of difficulty for applicants. The median days to allowance is 1146, which serves as a benchmark for the time required to reach a grant. With 722 resolved cases, the data provides a reliable perspective on the examiner's tendencies.
The interview lift for this examiner is 54.7 percent. This is an extremely high lift, indicating that interviews are exceptionally effective in this examiner's practice compared to the 54.6 percent baseline. Practitioners should prioritize direct communication to leverage the 54.7 percent lift. The 1146 median days to allowance is a key consideration for the timeline in Art Unit 1613. Given the 722 resolved cases, the 54.7 percent interview lift offers a powerful path to improve the 54.6 percent probability of allowance.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18450122 | BIOERODIBLE CROSSLINKING HYDROGEL BASED ON MULTI-ARM POLYOXAZOLINES WITH CAGE-LIKE SILICON-OXYGEN CORES | Non-Final OA | Boston Scientific Scimed, Inc. |
| 18141138 | NANOFIBROUS TISSUE ENGINEERING MATRICES WITH IMPROVED CLINICAL HANDLING PROPERTIES FOR PERIODONTAL AND CRANIOFACIAL REGENERATION AND METHODS OF MAKING THE SAME | Final Rejection | REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 17625962 | Herbicidal Mixtures Containing Amine Salts of Acidic Herbicides | Non-Final OA | MONSANTO TECHNOLOGY LLC |
| 17626469 | MULTI-AGENT OCULAR FORMULATIONS AND TREATMENT METHODS | Final Rejection | University of Utah Research Foundation |
| 18729020 | LIPIDIC COMPOUNDS, AND USES THEREOF | Final Rejection | SANOFI |
| 18412205 | REVERSE THERMAL GELS AND THEIR USE AS VASCULAR EMBOLIC REPAIR AGENTS | Non-Final OA | The Regents Of The University Of Colorado, A Body Corporate |
| 17639265 | LIPOSOMAL TROPONOID COMPOUND FORMULATIONS | Non-Final OA | United States Government As Represented By The Department of Veterans Affairs |
| 18722974 | PHOTODIMERIZABLE POLYMERS COMPRISING AT LEAST ONE POLYOXYALKYLENE GROUP, COMPOSITION COMPRISING SAME AND COSMETIC TREATMENT PROCESS | Non-Final OA | L'Oreal |
| 17962515 | PROCESS FOR ALTERING THE COLOR OF KERATIN FIBERS | Non-Final OA | L'Oreal |
| 18775053 | Diagnosis and Treatment of Metabolic Syndrome with Magnesium Compositions | Non-Final OA | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS |
| 18902135 | POLYMER NANOPARTICLE COMPOSITIONS FOR NON-VIRAL GENE DELIVERY TO THE CENTRAL NERVOUS SYSTEM | Final Rejection | BATTELLE MEMORIAL INSTITUTE |
| 17923448 | EMULSIFIER AND EMULSION COMPOSITION CONTAINING SAME | Non-Final OA | SHIN-ETSU CHEMICAL CO., LTD. |
| 18792590 | DRUG-LOADED LIPOSOMES AND USES THEREOF IN TREATING BIOFILM | Non-Final OA | Yeda Research and Development Co. Ltd. |
| 18579943 | Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disorders | Non-Final OA | Lapix Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy